Pō a Ao Healing Sanctuary

01 · Understanding the medicine

What is Ibogaine?

Ibogaine is a psychoactive indole alkaloid derived from Tabernanthe iboga, a West-Central African shrub. Modern research has focused mainly on opioid withdrawal and substance-use disorders. Small observational studies report rapid reductions in withdrawal symptoms and, for some participants, reduced or stopped opioid use; depressive symptoms have also improved in some follow-ups. These findings are promising but not proof of efficacy: the evidence base is small, heterogeneous, often uncontrolled, and includes serious medical complications and deaths. A systematic review found 24 clinical studies involving 705 people, including only a small number of controlled trials 1. A 12-month observational study reported improvement among a small cohort, but one participant died during treatment and only eight completed all follow-ups 2. Ibogaine is not presented here as a cure or as personal treatment advice.

02 · The science

How it works

Ibogaine is converted in the body, primarily by CYP2D6, to noribogaine, which remains active for longer. Laboratory and animal research indicate effects across several systems, including opioid, serotonin, NMDA, and sigma-related signaling; no single mechanism explains the reported changes in withdrawal, craving, perception, and mood. Human pharmacology is variable because CYP2D6 genetics and interacting medicines can alter exposure. Ibogaine and noribogaine also affect cardiac ion channels, helping explain QT-interval prolongation and arrhythmia risk 3. Mechanistic plausibility is not clinical proof.

03 · Hope, with context

What researchers are exploring

Potential benefit is not a promised outcome. The study population, support, setting, and evidence quality all matter.

Acute reduction in opioid-withdrawal symptoms

Open-label and observational studies report lessened withdrawal after administration. This signal is clinically interesting, but expectancy, selection, concurrent care, and the absence of robust published randomized efficacy results limit interpretation 1 2.

Preliminary human evidence; not established care.

Source 1 Source 2

Possible reduction in opioid use or craving

Some follow-up participants reported cessation or sustained reduction in opioid use, and reviews describe reduced craving. These outcomes come largely from small, non-randomized samples and may not generalize to people with different medical, social, or treatment histories 1 2.

Promising but low-certainty observational evidence.

Source 1 Source 2

Possible mood or trauma-related improvement

Depressive and trauma-related symptoms improved in some studies, but these were secondary or uncontrolled findings. Ibogaine has not been established as an approved treatment for depression, PTSD, or other psychiatric conditions 1.

Preliminary and insufficient for clinical conclusions.

Source 1

04 · Informed decisions

Safety & medication interactions

Do not start, stop, combine, or taper medicines based on this page. Discuss your complete medication list and health history with your prescriber or pharmacist.

Cardiac arrhythmia and sudden death

Ibogaine can prolong the QT interval, slow heart rate, and in susceptible circumstances contribute to torsades de pointes, ventricular arrhythmia, cardiac arrest, or death. A monitored observational study found clinically relevant QTc prolongation even in screened participants 3.

Source 1 Source 3

Neurological and physical impairment

Ataxia, dizziness, nausea, vomiting, tremor, and prolonged altered consciousness can impair judgment and mobility. Seizures and other serious neurological events have been reported; the review literature also raises neurotoxicity concerns 1.

Source 1 Source 3

Psychiatric destabilization

The intense, long-lasting experience can include fear, confusion, perceptual changes, insomnia, or worsening of underlying psychiatric vulnerability. Published studies commonly excluded people with psychosis, severe depression, suicidality, or major medical illness, so safety in those groups is uncertain 3.

Source 1 Source 3

Variable exposure and medical emergencies

CYP2D6 genetic differences, product variability, dehydration, electrolyte disturbance, liver or kidney disease, and unsupervised settings can change risk. Fatalities have occurred in clinical literature, and screening cannot eliminate all danger 1 3.

Source 1 Source 3

Interaction considerations

Ibogaine and noribogaine are metabolized through pathways that include CYP2D6, while ibogaine can affect cardiac repolarization. Medicines or substances that prolong QT, alter CYP2D6 or other relevant enzymes, depress the central nervous system, or change opioid tolerance may increase risk. Combining ibogaine with opioids, stimulants, alcohol, serotonergic medicines, or unverified supplements is not predictable. Interaction review requires a qualified clinician and an ECG- and medical-monitoring plan; this entry does not provide a washout schedule or combination protocol.

Explore the Safety Center

05 · The wider story

History, culture & legal context

Iboga is a living sacred plant in Bwiti traditions of Gabon and neighboring parts of Central Africa, where initiation and ceremony belong to specific communities, lineages, responsibilities, music, and spiritual meanings. That cultural context should not be collapsed into a Western clinical intervention, and clinical research should not be used to appropriate or flatten Indigenous practice. Modern ibogaine studies are usually medicalized, small, and focused on substance-use outcomes; they do not validate every ceremonial or commercial claim.

Legal context

Legal status varies substantially by country and sometimes by state or province. In the United States, ibogaine is not FDA-approved; FDA describes psychedelic work as drug development and notes that allowing an early-phase noribogaine study to proceed is not an approval of safety or effectiveness 4. ClinicalTrials.gov lists an ibogaine Phase 1/2 study for opioid withdrawal as completed, while noting that registry listing is not government approval 4. Laws elsewhere change, and possession, import, administration, and clinical research may be regulated differently; check current official local rules.

06 · Beyond the experience

Preparation & integration

Before

Because of the possibility of fatal cardiac events and psychiatric complications, any legitimate research use requires formal informed consent, careful medical and psychiatric assessment, medication and substance review, ECG and laboratory evaluation, continuous or repeated monitoring, and emergency capability. Preparation also includes discussing alternatives for opioid-use disorder and overdose prevention. This is safety education, not a recommendation to seek or self-administer ibogaine, and no dosing or sourcing instructions are provided.

After

Aftercare should be voluntary, culturally respectful, and connected to evidence-based substance-use and mental-health care rather than framed as a guaranteed transformation. Useful planning may include follow-up for withdrawal, cravings, sleep, mood, suicidality, cardiac symptoms, and return to opioid use, with rapid access to emergency and addiction services. A single experience does not replace ongoing treatment, social support, or overdose-prevention planning.

Questions to bring to your care team

What human evidence exists for the specific condition, population, and outcome being discussed, and how much comes from controlled trials rather than self-report or case series?
What cardiac, psychiatric, medication, and substance-use factors could make ibogaine especially dangerous, and is there genuine emergency medical capacity?
How are Indigenous Bwiti knowledge and community rights being acknowledged without presenting ceremony as a clinical protocol?

Preparation guide →Integration support →

07 · Follow the evidence

Sources & further reading

Read the original work. Publication is not endorsement, and a source check is not independent clinical review.